New combo therapy aims to stop rare organ disease
NCT ID NCT07388602
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase 3 trial tests whether adding the experimental drug SCTC21C to standard chemotherapy (bortezomib, cyclophosphamide, dexamethasone) works better than chemo alone for people newly diagnosed with AL amyloidosis. The study will enroll 90 participants and measure how well the treatment clears abnormal proteins from the blood and delays organ damage. The goal is to find a more effective way to control this rare disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCTC21C (a drug given as an injection under the skin) combined with bortezomib, cyclophosphamide, and dexamethasone (standard chemotherapy)
What this could lead to
If successful, this combination could become a new standard treatment for newly diagnosed AL amyloidosis, improving blood response rates and delaying organ damage.
What could go wrong
This is an early Phase 3 trial with only 90 participants, so results may not apply to all patients. Adding a new drug also raises the chance of side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.